RLY-5836
RLY-5836-101
Phase 1 small_molecule completed
Quick answer
RLY-5836 for PIK3CA Mutation is a Phase 1 program (small_molecule) at Relay Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Relay Therapeutics
- Indication
- PIK3CA Mutation
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed